Belsomra Complete Drug-Drug Interaction Profile

How Suvorexant Works: Mechanism Relevant to Drug Interactions

Suvorexant blocks both OX1R and OX2R orexin receptors, silencing the wake-promoting hypocretin/orexin signaling axis rather than broadly depressing GABA-A activity. This mechanism is pharmacologically distinct from benzodiazepines and Z-drugs, which enhances the safety margin for respiratory depression when used alone. The interaction profile, however, is still substantial because suvorexant's plasma exposure is almost entirely controlled by hepatic CYP3A4 activity.

The Orexin System and Wake Drive

Orexin neurons in the lateral hypothalamus project broadly to noradrenergic, histaminergic, dopaminergic, and cholinergic wake-promoting nuclei. Blocking both receptor subtypes simultaneously produces sleep without the global CNS suppression seen with GABAergic drugs. Herring et al. Demonstrated this in the key Phase 3 trial (N=1,021): suvorexant 20 mg reduced subjective time to sleep onset and wake after sleep onset versus placebo over 3 months without meaningful next-morning residual sedation at approved doses 1.

Why CYP3A4 Controls Everything

The FDA prescribing label documents that CYP3A4 accounts for the vast majority of suvorexant oxidative clearance, with CYP2C19 playing a minor secondary role 2. Because there is no meaningful renal excretion of unchanged drug, hepatic enzyme activity is the single biggest lever on suvorexant plasma concentrations. A strong CYP3A4 inhibitor can multiply peak exposure (Cmax) and area under the curve (AUC) several-fold; a strong inducer can reduce AUC by more than 80%. Both directions carry clinical consequences.

Strong CYP3A4 Inhibitors: Contraindicated Combinations

Strong CYP3A4 inhibitors raise suvorexant exposure to a degree that cannot be safely managed by dose reduction. The FDA label lists this as a contraindication, not merely a precaution 2.

Which Drugs Are Affected

The contraindicated class includes:

• Azole antifungals: ketoconazole, itraconazole, posaconazole, voriconazole
• Macrolide antibiotics: clarithromycin (not azithromycin, which is a weak inhibitor)
• HIV protease inhibitors: ritonavir, lopinavir/ritonavir, atazanavir, nelfinavir, indinavir
• Other antivirals: cobicistat-containing regimens, boceprevir, telaprevir

In a dedicated pharmacokinetic interaction study cited in the FDA label, co-administration with ketoconazole (a prototypical strong CYP3A4 inhibitor) raised suvorexant AUC approximately 3-fold and Cmax approximately 2-fold 2. At those exposure levels, the risks of next-morning psychomotor impairment, excessive sedation, and complex sleep behaviors increase substantially.

Clinical Decision Point

If a patient currently taking suvorexant requires a course of clarithromycin for community-acquired pneumonia, the correct approach is to suspend suvorexant for the duration of antibiotic therapy rather than attempt a dose adjustment. The interaction is too steep to titrate around safely.

Moderate CYP3A4 Inhibitors: The 5 mg Dose Cap

When the inhibitor is moderate rather than strong, the FDA permits continued suvorexant use at a maximum dose of 5 mg nightly 2. The 5 mg tablet exists specifically for this scenario.

Common Moderate Inhibitors Encountered in Practice

• Calcium channel blockers: diltiazem, verapamil (both widely used for hypertension and rate control in atrial fibrillation)
• Azole antifungals at lower potency: fluconazole (moderate at standard 150 mg doses)
• Macrolides: erythromycin
• Antiarrhythmics: dronedarone
• Antidepressants: fluvoxamine (also a potent CYP1A2 inhibitor; primarily moderate for CYP3A4)
• Aprepitant and fosaprepitant: used as antiemetics, these carry a moderate CYP3A4 inhibitory effect lasting several days post-dose

Diltiazem and verapamil deserve particular attention because they are long-term medications. A patient stabilized on suvorexant 20 mg who is then started on diltiazem for rate control could experience double or triple the intended exposure. Reducing to 5 mg is not optional at that point.

Duration of Inhibition After Drug Discontinuation

Some inhibitors have residual effects. Fluconazole, for example, has a half-life of approximately 30 hours; its CYP3A4 inhibitory effect persists for roughly 2 to 5 days after the last dose. Suvorexant should remain at 5 mg during that washout window.

CYP3A4 Inducers: Loss of Efficacy

Strong inducers dramatically reduce suvorexant plasma concentrations, potentially rendering the drug ineffective at any approved dose.

Strong Inducers

• Antibiotics: rifampin (rifampicin)
• Antiepileptics: carbamazepine, phenytoin, phenobarbital, oxcarbazepine
• Herbal preparations: St. John's Wort (Hypericum perforatum), which patients frequently do not consider a drug and may not report spontaneously

Co-administration with rifampin in pharmacokinetic studies reduced suvorexant AUC by more than 80% 2. At those reduced exposures, the 20 mg dose may provide little to no sleep benefit. The FDA label recommends avoiding concomitant use with strong inducers. Patients on long-term antiepileptic therapy who also need pharmacotherapy for insomnia may need to consider alternative agents that do not rely on CYP3A4 for clearance.

Moderate Inducers

Moderate inducers such as bosentan, nafcillin, and modafinil produce smaller but still meaningful reductions. If suvorexant efficacy wanes unexpectedly, checking the medication list for a recently added moderate inducer is a productive first step.

CNS Depressants: Additive Sedation and Psychomotor Impairment

Suvorexant adds to the sedative effects of any drug that depresses CNS activity, including benzodiazepines, Z-drugs, first-generation antihistamines, antipsychotics, tricyclic antidepressants, muscle relaxants, and gabapentinoids.

Quantifying the Risk

A post-hoc analysis of Phase 3 suvorexant data found that next-morning driving impairment was dose-related, with the 40 mg dose (not FDA-approved) producing effects comparable to a blood alcohol concentration of approximately 0.05% on a standardized driving test 3. Adding a CNS depressant to even an approved 20 mg dose could reproduce that degree of impairment.

Specific Drug Classes

Benzodiazepines and Z-drugs: combining suvorexant with zolpidem, eszopiclone, zaleplon, temazepam, or triazolam is not recommended. Each agent individually carries complex sleep behavior warnings; stacking them multiplies risk without additional sleep benefit.

First-generation antihistamines: diphenhydramine (found in OTC sleep aids, allergy medications, and many combination cold products) adds H1 blockade-mediated sedation on top of suvorexant's orexin blockade. Patients must be counseled about over-the-counter product labels.

Antipsychotics and tricyclics: quetiapine, mirtazapine, and amitriptyline are sometimes used off-label for sleep. Adding suvorexant significantly increases next-morning sedation risk, and dose reduction should be considered.

Gabapentin and pregabalin: these agents produce dose-dependent sedation that compounds suvorexant's effects. The combination is common in patients with comorbid pain and insomnia; monitoring for over-sedation is warranted.

Opioids: FDA Black-Box Warning Territory

The co-administration of any CNS depressant with opioids carries an FDA-mandated black-box warning. Suvorexant is included in this category 2.

Respiratory Depression Risk

Unlike benzodiazepines, suvorexant does not appear to meaningfully suppress hypercapnic ventilatory response when used alone at approved doses. A clinical pharmacology study in patients with mild-to-moderate obstructive sleep apnea showed that suvorexant 40 mg did not worsen the apnea-hypopnea index compared to placebo 4. That relative respiratory safety profile is erased when opioids are added. Opioid-induced respiratory depression is centrally mediated through mu-receptors; the additive CNS depression from suvorexant lowers the threshold for clinically significant hypoventilation.

Practical Guidance

For patients on long-term opioid therapy for chronic pain who also need sleep pharmacotherapy, the prescribing decision should involve a documented risk-benefit discussion. If suvorexant is chosen, 5 mg rather than 10 mg is a reasonable starting dose, and the patient should be counseled to avoid additional CNS depressants.

Alcohol: Time-Course Matters

Alcohol is a CYP3A4 substrate at high concentrations, but its primary interaction with suvorexant is pharmacodynamic, not pharmacokinetic. Both compounds produce CNS depression, and the overlap in timing is critical.

Suvorexant reaches peak plasma concentration (Tmax) approximately 2 hours after ingestion. Alcohol consumed within 3 to 4 hours of bedtime overlaps with this peak. The FDA label notes that next-morning psychomotor impairment was observed when suvorexant 20 mg was combined with alcohol, even at moderate alcohol doses 2. Patients should be advised to avoid alcohol on the same evening as suvorexant administration.

P-Glycoprotein Inhibition: The Digoxin Interaction

Suvorexant inhibits P-glycoprotein (P-gp) transport. Because digoxin is a P-gp substrate with a narrow therapeutic index, this interaction has clinical significance.

Magnitude of the Interaction

In a dedicated drug-drug interaction study, suvorexant raised digoxin AUC by approximately 12% and Cmax by approximately 30% 2. A 30% Cmax increase is enough to push a patient near the upper boundary of the therapeutic range, particularly elderly patients who may already have reduced renal clearance of digoxin. Digoxin serum concentrations should be monitored when suvorexant is initiated or discontinued in patients taking digoxin.

Other P-gp Substrates

While digoxin has the most evidence, other narrow-therapeutic-index P-gp substrates warrant attention: colchicine (in renal impairment), certain topotecan formulations, and some direct oral anticoagulants (dabigatran is a P-gp substrate). The clinical significance of these co-administrations is less well-characterized; caution and monitoring are reasonable.

Special Populations That Amplify Interaction Risk

The following framework identifies patient profiles where multiple interaction vectors converge, substantially raising the overall risk of suvorexant-related adverse events.

Elderly Patients

Adults over 65 years often have reduced CYP3A4 hepatic activity at baseline, polypharmacy with CNS-active medications, and declining renal function that impairs digoxin clearance. A 70-year-old taking diltiazem for atrial fibrillation, gabapentin for neuropathy, and then prescribed suvorexant 20 mg faces three simultaneous interaction risks: moderate CYP3A4 inhibition from diltiazem (mandating the 5 mg cap), additive CNS depression from gabapentin, and the P-gp digoxin interaction if digoxin is also in the regimen.

The American Academy of Sleep Medicine notes that older adults are particularly susceptible to next-morning psychomotor impairment from sedative-hypnotics 5.

Patients with Hepatic Impairment

Severe hepatic impairment independently reduces suvorexant clearance because CYP3A4 is a hepatic enzyme. The FDA label states that suvorexant is not recommended in severe hepatic impairment 2. Moderate hepatic impairment raises AUC by approximately 17%, which is not large enough to require dose adjustment on its own, but compounds the effect of any co-administered inhibitor.

Patients with Obesity

CYP3A4 activity and volume of distribution both vary with adiposity. Suvorexant's long half-life (approximately 12 hours) may extend further in patients with high adipose mass, raising next-morning concentrations and amplifying interactions with CNS depressants taken in the evening.

Drug Interactions with Antidepressants and Mood Stabilizers

SSRIs and SNRIs

SSRIs as a class are not clinically significant CYP3A4 inhibitors, with one exception: fluvoxamine is a potent CYP1A2 and moderate CYP3A4 inhibitor. Patients on fluvoxamine for OCD or depression who are prescribed suvorexant should use the 5 mg dose cap.

Sertraline, escitalopram, fluoxetine, and venlafaxine do not require suvorexant dose adjustment based on CYP3A4 interactions, though pharmacodynamic CNS additive effects remain possible.

Lithium

Lithium is renally cleared and does not interact with CYP3A4. No pharmacokinetic interaction with suvorexant is expected. The clinical concern in this combination is additive neurotoxicity risk if sedation reduces mobility and fluid intake, which can concentrate lithium.

Valproate

Valproate is not a significant CYP3A4 inducer or inhibitor, but it is a substrate of several other enzymes and produces CNS depression. The combination with suvorexant carries additive sedation risk without a pharmacokinetic interaction requiring dose adjustment.

Contraceptives, Antibiotics, and Short-Course Drug Interactions

Oral Contraceptives

Hormonal contraceptives are minor CYP3A4 substrates but are not meaningful inhibitors. No dose adjustment of suvorexant is required based on oral contraceptive co-administration.

Fluoroquinolones

Ciprofloxacin is a moderate CYP1A2 inhibitor but not a meaningful CYP3A4 inhibitor. No suvorexant dose adjustment is expected. Metronidazole similarly lacks CYP3A4 inhibitory activity at clinical doses.

Azithromycin vs. Clarithromycin

This distinction matters at the bedside. Clarithromycin is a strong CYP3A4 inhibitor and is contraindicated with suvorexant. Azithromycin is not a meaningful CYP3A4 inhibitor and does not require suvorexant modification. When selecting antibiotic therapy for a patient on suvorexant, azithromycin is the macrolide of choice.

Summary Interaction Table

| Co-administered Drug/Class | Interaction Mechanism | Clinical Action | |---|---|---| | Ketoconazole, itraconazole, ritonavir, clarithromycin | Strong CYP3A4 inhibition | Contraindicated | | Diltiazem, verapamil, fluconazole, erythromycin, dronedarone | Moderate CYP3A4 inhibition | Cap suvorexant at 5 mg | | Rifampin, carbamazepine, phenytoin, St. John's Wort | Strong CYP3A4 induction | Avoid combination | | Opioids | Additive CNS/respiratory depression | FDA black-box; use lowest dose; document risk-benefit | | Benzodiazepines, Z-drugs | Additive CNS depression | Avoid combination; if unavoidable, reduce suvorexant | | Diphenhydramine, first-gen antihistamines | Additive CNS depression | Counsel on OTC risk; use 5 mg if combination unavoidable | | Gabapentin, pregabalin | Additive sedation | Monitor; consider suvorexant dose reduction | | Digoxin | P-gp inhibition by suvorexant | Monitor digoxin levels at initiation/discontinuation | | Alcohol | Pharmacodynamic CNS additive | Avoid alcohol same evening | | Azithromycin | Negligible CYP3A4 effect | No adjustment required |

What the Evidence Says About Interaction-Related Adverse Events

The suvorexant Phase 2/3 clinical program included approximately 3,000 patients across trials, with safety data consolidated in the FDA's medical review 2. Somnolence was the most commonly reported adverse event at 7% versus 3% placebo at 20 mg. Rates of complex sleep behaviors (sleep-driving, sleep-eating) were lower than Z-drug historical comparisons, which the FDA attributed in part to the absence of GABAergic activity. However, the label still carries a boxed warning for complex sleep behaviors because cases have been reported.

Johnson et al. (J Clin Sleep Med, 2015) noted in a post-marketing review that the majority of reported complex sleep behaviors with suvorexant occurred in patients co-ingesting alcohol or another CNS depressant, consistent with a pharmacodynamic interaction amplifying the risk 6.

The clinical pharmacology review on file at the FDA confirms that suvorexant does not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2D6, or CYP2C19 at clinically relevant concentrations, which means it is unlikely to raise plasma levels of drugs metabolized by those pathways 2.

As the FDA prescribing information states directly: "Concomitant use of suvorexant with other CNS depressants including alcohol increases the risk of next-day psychomotor impairment, including impaired driving" 2.

The American Academy of Sleep Medicine's 2017 clinical practice guideline for chronic insomnia treatment stated: "We suggest that clinicians use suvorexant as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults," while explicitly noting that provider judgment about CNS depressant co-administration must precede every prescription 5.